Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
P/B ratio for Foghorn Therapeutics Inc. (FHTX)
P/B ratio as of 2023: -3.51
According to Foghorn Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -3.51. At the end of 2022 the company had a P/B ratio of 2369.23.
P/B ratio history for Foghorn Therapeutics Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -3.51 |
| 2022 | 2369.23 |
| 2021 | 8.78 |
| 2020 | 5.10 |
| 2019 | -7.58 |
| 2018 | -9.06 |